GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Micro-glucagon

Company
Insel Gruppe AG, University Hospital Bern
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for Micro-glucagon and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06770621

    Longitudinal Study of the GLUcagon REsponse to Hypoglycemia in Children and Adolescents With New-onset Type 1 DIAbetes

    Not yet reported Cliniques universitaires Saint-Luc- Université Catholique de Louvain 1000 participants Est. completion 2025-10-25 1 site
    Other conditions: Severe Hypoglycemia, Type1diabetes
    View official trial listing →
  • Recruiting NCT NCT07224880

    Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists

    Cytrellis Biosystems, Inc. 10 participants Est. completion 2026-02-28 1 site
    Other conditions: glp1 Agonist, Gene Expression, Skin Laxity
    View official trial listing →
  • Completed NCT NCT02916251

    ZP4207(Dasiglucagon) Administered to T1D Patients to Assess the PK and PD Compared to Marketed Glucagon

    Not yet reported Zealand Pharma 38 participants Est. completion 2017-04-05 1 site
    Other conditions: Diabetes Mellitus Type 1
    View official trial listing →
  • Completed NCT NCT04009603

    Comparison of Probiotics, Metformin & Their Combination Therapy in the Treatment of PCOS

    Not yet reported Ziauddin University 78 participants Est. completion 2020-01-28 1 site
    Other conditions: Polycystic Ovary Syndrome
    View official trial listing →
  • Withdrawn NCT NCT04192019

    Micro Glucagon During Exercise in Type 1 Diabetes

    Not yet reported Insel Gruppe AG, University Hospital Bern Est. completion 2024-06 Stand-alone
    Other conditions: Type 1 Diabetes, Hypoglycemia
    View official trial listing →
  • Terminated NCT NCT05960565

    Glucagon Enhanced Insulin Absorption in Diabetes Mellitus Type 1

    Not yet reported St. Olavs Hospital 9 participants Est. completion 2023-12-22 1 site
    Other conditions: Type 1 Diabetes
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.